Key facts
- Moximed’s last known valuation is $170.0M.
- It has raised $316.0M across 3 recorded rounds; the latest was Later Stage VC ($62.7M) in Aug 2024.
- Notable investors include New Enterprise Associates, Cormorant Asset Management, Frazier Healthcare Partners, Gilde Healthcare, Lightstone Ventures — 15 tracked in total.
- Moximed has filed 6 Form Ds with the SEC since 2009, most recently Aug 2024 ($62.7M sold to 35 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Moximed
Funding rounds
3 roundsAbout Moximed
Developer of unicompartmental load absorber implants designed to improve the standard of care for patients with osteoarthritis. The company's implants provide osteoarthritis treatment by minimizing joint pain, providing dynamic load reduction, and potentially delaying or avoiding the need for more invasive surgeries, enabling doctors to help patients maintain an active lifestyle.
- Sector
- Healthcare
- HQ
- Fremont, CA, United States
- Founded
- 2007
- Employees
- 40
- Website
- moximed.com/
- Ownership
- Privately Held (backing)
Moximed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Moximed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Moximed in its N-PORT filings yet. We sweep new filings monthly.